New Parkinson's drug candidate passes early safety check

NCT ID NCT04291859

Completed Symptom relief Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new drug called Lu AF28996 in 57 people with Parkinson's disease. The main goal was to see if the drug is safe and how the body handles it. Researchers measured side effects and drug levels in the blood. This is a first step to see if the drug might help control symptoms in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu AF28996
What this could lead to: If successful, this could point toward a new medication to help control Parkinson's symptoms.
What could go wrong: This is a very early Phase 1 study focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Caen Normandy University

Caen, Basse-Normandie, 14033, France
CenExel Los Alamitos

Los Alamitos, California, 90720, United States
Curiositas-ad-sanum

Hamburg, 83527, Germany
Georgetown University

Washington D.C., District of Columbia, 20007, United States
Hawaii Pacific Neuroscience

Honolulu, Hawaii, 96817, United States
Hosp. General Catalunya

Mira-Sol, 08195, Spain
Hospital Vall d´Hebron

Barcelona, 08035, Spain
Inland Nortwest Research

Spokane, Washington, 99202, United States
Neurology Consultants of Nebraska

Omaha, Nebraska, 68154, United States
Parkinson's Disease Treatment Center of SW FL

Port Charlotte, Florida, 33980, United States
QPS Netherlands BV

Leeuwarden, 8934 AD, Netherlands
QUEST Research Institute

Farmington Hills, Michigan, 48334, United States
Velocity

Hallandale, Florida, 33009, United States
Virgen Del Roccio

Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.